New obesity pill enters human testing

NCT ID NCT07310901

Summary

This is an early-stage study to test a new daily pill called CRB-913 for weight loss in people with obesity. The main goals are to see if the drug is safe, how the body processes it, and if it helps reduce body weight. About 252 participants will take either the drug or a placebo (a dummy pill) for 12 weeks, followed by a month of monitoring.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESE BUT OTHERWISE HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Accel Research Sites

    RECRUITING

    DeLand, Florida, 32720, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Alliance Clinical

    RECRUITING

    Las Vegas, Nevada, 89109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Arizona Clinical Trials

    RECRUITING

    Chandler, Arizona, 85225, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Central Alabama Research

    RECRUITING

    Birmingham, Alabama, 35209, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Flourish Research

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Louisville Metabolic and Atherosclerosis Research Center

    RECRUITING

    Louisville, Kentucky, 40213, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Lucas Research

    RECRUITING

    Morehead City, North Carolina, 28557, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Medpace Clinical Pharmacology

    RECRUITING

    Cincinnati, Ohio, 45227, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Neurobehavioral Research

    RECRUITING

    Cedarhurst, New York, 11516, United States

    Contact

    Contact Phone: •••-•••-••••

  • Prospective Research Innovations

    RECRUITING

    Rancho Cucamonga, California, 91730, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Quotient Sciences

    RECRUITING

    Miami, Florida, 33126, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Rochester Clinical Research

    RECRUITING

    Rochester, New York, 14609, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Tampa Bay Medical Research

    RECRUITING

    Largo, Florida, 33761, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Velocity Clinical Research

    RECRUITING

    Cleveland, Ohio, 44122, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Velocity Clinical Research

    RECRUITING

    Dallas, Texas, 75230, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.